Brought to you by 
Alkermes applies ProLease to EPO for J&J; J&J ends deal
26 Jul 2000
Executive Summary
Alkermes (drug delivery) will apply its ProLease injectable sustained release drug delivery technology to J&J division RW Johnson Pharmaceutical's erythropoietin for non-dialysis applications, in its third drug delivery deal with J&J.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alkermes applies ProLease to EPO for J&J; J&J ends deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice